News from ISGlobal
Preliminary results have been obtained from the Adaptive COVID-19 Treatment Test (ACTT) global clinical trial conducted by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). These first results show that hospitalized patients with severe COVID-19 and lung involvement treated with the antiviral remdesivir recovered faster than patients who received placebo.
This international multicentre trial included a total of 1063 patients and, in Spain, it has been coordinated by the Germans Trias i Pujol Hospital. It also involved the participation of the Barcelona Institute for Global Health (ISGlobal) and the Hospital Clínic.
The obtained results are the following:
- The recovery time in patients who received remdesivir was 31% shorter than in those who received placebo, with a 4-day reduction in hospitalization time, from 15 to 11 days.
- The results also suggest a benefit in survival, with a lethality of 8% for the treated group versus 11.6% for the placebo group.
"These preliminary results are very promising, but we will have to wait for the final analysis to assess the final efficacy of remdesivir and the best time for its administration", concludes the Head of the International Health Service at Hospital Clinic and ISGlobal researcher, José Muñoz.